Sussex Drug Discovery Centre (SDDC)

Work with US

In order to succeed in our goals of drug discovery and development, we strive to work with others who share our interests. We welcome contact from individuals and groups with whom we can work together to prosecute target validation and drug discovery projects, and from those that are interested in joining us.


Join the SDDC

We welcome applications from talented individuals who are interested in pursuing a career in drug discovery. Current opportunities are posted below.



We actively welcome enquiries regarding collaborative drug discovery opportunities, particularly in our core research interest areas:

  • Neuroscience

  • DNA damage repair for oncology

  • Respiratory diseases

In particular we seek partners from pharma, biotech and academia with whom we can collaborate to accelerate the progression of early stage assets through to the delivery of clinical candidates and beyond. The SDDC has developed a successful model for achieving this including the progression of assets from pharma and biotech company projects suspended due to internal strategy changes.

Recent examples of how the SDDC collaborates:



re-Viral is an emerging UK based biopharma focussed on developing first in class antivirals. A streamlined lead optimisation project was prosecuted in collaboration with the SDDC through funding via the Wellcome Trust’s prestigious Seeding Drug Discovery program.

The key goals of this project were to identify a drug candidate suitable for progression into studies in man and novel backup compounds with the ambition of developing the first approved therapy for Respiratory Syncitial Virus (RSV).



Enterprise is a venture backed, early stage, respiratory drug discovery company based at the Sussex Innovation Centre. Enterprise works with the SDDC to develop novel drugs for the treatment of respiratory diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma. The relationship allows Enterprise to access the considerable drug discovery expertise of the SDDC along with state of the art capabilities in respiratory epithelial biology and ion channel drug discovery.



Schizophrenia is a major unmet medical need affecting 1% of the population. Although many of the disease symptoms, such as paranoia, are well managed others, such as impaired cognitive function, are not. After securing access to a deprioritised program within GlaxoSmithKline and successfully obtaining funding from the Wellcome Trust, the SDDC is progressing a program to design and develop AMPA receptor modulators as novel drugs for treating the cognitive dysfunction associated with schizophrenia and other CNS disorders.



Please contact SDDC for details 

For further information

Please contact us by E-mail: